Trials / Completed
CompletedNCT00549718
Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia
A Phase 3 Randomized, Placebo-Controlled, CLinical Trial to Study the Safety and Efficacy of Three Doses of Lurasidone HCl in Acutely Psychotic Patients With Schizophrenia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 489 (actual)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. The study will also evaluate the safety and tolerability of lurasidone as compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lurasidone HCl | Once daily |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2007-10-26
- Last updated
- 2014-06-11
- Results posted
- 2010-12-14
Locations
48 sites across 7 countries: United States, France, India, Malaysia, Romania, Russia, Ukraine
Source: ClinicalTrials.gov record NCT00549718. Inclusion in this directory is not an endorsement.